Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis

摘要: Aim Recent studies have suggested that intravenous (i.v.) enoxaparin could be used as antithrombotic therapy in patients ongoing percutaneous coronary intervention (PCI). However, anti-Xa pharmacokinetics following different i.v. dosing regimens is not clearly established. Methods A population pharmacokinetic analysis was developed using activities measured 546 who received a single 0.5 mg kg−1 dose of immediately before PCI. Effects higher doses (0.75 mg kg−1 and 1 mg kg−1) and/or additional bolus after the initial administration were similarly simulated. Results Enoxaparin time profiles best described by one-compartment model with zero-order kinetics. Mean parameters (intersubject variability, %) CL 1.2 l h−1 (33), V 2.9 l (30) input 0.25 h (24). With 0.5 mg kg−1, totality reached an effective anticoagulation level (anti-Xa >0.5 IU ml−1) only 2.5% levels above 1.5 IU ml−1. Simulations showed greater prolonged duration (3.4 4.1 h, respectively) compared (2.7 h) markedly increased proportion (48% 79%, >1.5 IU ml−1. For delayed procedures, administered second half interval between 90 min to 2 h order maintain similar profile levels. Conclusions A adequately should safer for undergoing elective An proposed or procedures.